154 related articles for article (PubMed ID: 38049077)
81. Immune-related pneumonitis associated with immune checkpoint inhibitors in lung cancer: a network meta-analysis.
Chen X; Zhang Z; Hou X; Zhang Y; Zhou T; Liu J; Lin Z; Fang W; Yang Y; Ma Y; Huang Y; Zhao H; Zhang L
J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32863271
[TBL] [Abstract][Full Text] [Related]
82. Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trial.
Diefenbach CS; Hong F; Ambinder RF; Cohen JB; Robertson MJ; David KA; Advani RH; Fenske TS; Barta SK; Palmisiano ND; Svoboda J; Morgan DS; Karmali R; Sharon E; Streicher H; Kahl BS; Ansell SM
Lancet Haematol; 2020 Sep; 7(9):e660-e670. PubMed ID: 32853585
[TBL] [Abstract][Full Text] [Related]
83. Checkpoint Immunotherapy in Pediatrics: Here, Gone, and Back Again.
Long AH; Morgenstern DA; Leruste A; Bourdeaut F; Davis KL
Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-14. PubMed ID: 35580293
[TBL] [Abstract][Full Text] [Related]
84. Excellent Response to Atezolizumab After Clinically Defined Hyperprogression Upon Previous Treatment With Pembrolizumab in Metastatic Triple-Negative Breast Cancer: A Case Report and Review of the Literature.
Feng D; Guan Y; Liu M; He S; Zhao W; Yin B; Liang J; Li Y; Wang J
Front Immunol; 2021; 12():608292. PubMed ID: 34135884
[TBL] [Abstract][Full Text] [Related]
85. [Clinical Efficacy of Monotherapy with Immune Checkpoint Inhibitors for Advanced Non-Small Cell Lung Cancer].
Sasaki T; Tabata T; Nonomura R; Oshima Y; Mitomo H; Ishibashi N; Sugawara T; Tezuka N; Sagawa M; Kondo T; Yoshimura N
Gan To Kagaku Ryoho; 2020 Oct; 47(10):1443-1447. PubMed ID: 33130738
[TBL] [Abstract][Full Text] [Related]
86. Do peripheral neuropathies differ among immune checkpoint inhibitors? Reports from the European post-marketing surveillance database in the past 10 years.
Ruggiero R; Balzano N; Di Napoli R; Fraenza F; Pentella C; Riccardi C; Donniacuo M; Tesorone M; Danesi R; Del Re M; Rossi F; Capuano A
Front Immunol; 2023; 14():1134436. PubMed ID: 37006303
[TBL] [Abstract][Full Text] [Related]
87. Challenges in sarcoidosis and sarcoid-like reactions associated to immune checkpoint inhibitors: A narrative review apropos of a case.
Apalla Z; Kemanetzi C; Papageorgiou C; Bobos M; Manoli M; Fotiadou C; Hatzibougias D; Boukovinas I; Stergiou E; Levva S; Lallas A; Lazaridou E
Dermatol Ther; 2021 Jan; 34(1):e14618. PubMed ID: 33263945
[TBL] [Abstract][Full Text] [Related]
88. Identifying and treating candidates for checkpoint inhibitor therapies in multiple myeloma and lymphoma.
Hradska K; Kascak M; Hajek R; Jelinek T
Expert Rev Hematol; 2020 Apr; 13(4):375-392. PubMed ID: 32116068
[No Abstract] [Full Text] [Related]
89. Immune checkpoint inhibitors plus chemotherapy versus chemotherapy alone as first-line therapy for advanced gastric and esophageal cancers: A systematic review and meta-analysis.
Noori M; Mahjoubfar A; Azizi S; Fayyaz F; Rezaei N
Int Immunopharmacol; 2022 Dec; 113(Pt A):109317. PubMed ID: 36252494
[TBL] [Abstract][Full Text] [Related]
90. Risk of scleroderma according to the type of immune checkpoint inhibitors.
Terrier B; Humbert S; Preta LH; Delage L; Razanamahery J; Laurent-Roussel S; Mestiri R; Beaudeau L; Legendre P; Goupil F; Hadjadj J; Stolzenberg MC; Treluyer JM; Westeel V; Valnet-Rabier MB; Wislez M; Mouthon L; Chouchana L
Autoimmun Rev; 2020 Aug; 19(8):102596. PubMed ID: 32540450
[TBL] [Abstract][Full Text] [Related]
91. Ovarian Cancer in the Era of Immune Checkpoint Inhibitors: State of the Art and Future Perspectives.
Maiorano BA; Maiorano MFP; Lorusso D; Maiello E
Cancers (Basel); 2021 Sep; 13(17):. PubMed ID: 34503248
[TBL] [Abstract][Full Text] [Related]
92. First-Line Treatment of Advanced Non-Small-Cell Lung Cancer with Immune-Checkpoint Inhibitors: New Combinations and Long-Term Data.
Boussageon M; Swalduz A; Chouaïd C; Bylicki O
BioDrugs; 2022 Mar; 36(2):137-151. PubMed ID: 35147894
[TBL] [Abstract][Full Text] [Related]
93. Toxicity of Immune-Checkpoint Inhibitors in Hematological Malignancies.
Hradska K; Hajek R; Jelinek T
Front Pharmacol; 2021; 12():733890. PubMed ID: 34483944
[TBL] [Abstract][Full Text] [Related]
94. Programmed Cell Death-One Inhibition Therapy in Classical Hodgkin Lymphoma.
Al-Hadidi SA; Chuang HH; Miranda RN; Lee HJ
Clin Lymphoma Myeloma Leuk; 2021 Feb; 21(2):e105-e111. PubMed ID: 33160934
[TBL] [Abstract][Full Text] [Related]
95. The Safety and Efficacy of Checkpoint Inhibitors in Transplant Recipients: A Case Series and Systematic Review of Literature.
Kumar V; Shinagare AB; Rennke HG; Ghai S; Lorch JH; Ott PA; Rahma OE
Oncologist; 2020 Jun; 25(6):505-514. PubMed ID: 32043699
[TBL] [Abstract][Full Text] [Related]
96. [Evaluation of Efficacy and Prognosis Analysis of Stage III-IV SMARCA4-deficient
Non-small Cell Lung Cancer Treated by PD-1 Immune Checkpoint Inhibitors plus
Chemotherapy and Chemotherapy].
Wang X; Tu M; Jia H; Liu H; Wang Y; Wang Y; Jiang N; Lu C; Zhang G
Zhongguo Fei Ai Za Zhi; 2023 Sep; 26(9):659-668. PubMed ID: 37985152
[TBL] [Abstract][Full Text] [Related]
97. Pediatric thyroid side effects of immune checkpoint inhibitors.
Morgante C; Fierabracci A; Grossi A
Trends Endocrinol Metab; 2024 Apr; ():. PubMed ID: 38637222
[TBL] [Abstract][Full Text] [Related]
98. Immune checkpoint inhibitors therapy as the game-changing approach for pediatric lymphoma: A brief landscape.
Ebrahimi S; Habibzadeh A; Khojasteh-Kaffash S; Valizadeh P; Samieefar N; Rezaei N
Crit Rev Oncol Hematol; 2024 Jan; 193():104225. PubMed ID: 38049077
[TBL] [Abstract][Full Text] [Related]
99. Real-world safety experience with immune checkpoint inhibitors in Saudi Arabia.
Al Nuhait M; Bajnaid E; Al Otaibi A; Al Shammari A; Al Awlah Y
Sci Prog; 2021; 104(1):36850421997302. PubMed ID: 33689534
[No Abstract] [Full Text] [Related]
100. Comparative efficacy and safety of immune checkpoint inhibitors for unresectable advanced melanoma: A systematic review and network meta-analysis.
Li Y; Liang X; Li H; Chen X
Int Immunopharmacol; 2023 Feb; 115():109657. PubMed ID: 36608446
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
